Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06668935 · ClinicalTrials.gov registry record

Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

A clinical trial of Diabetes Mellitus, sponsored by Abbott Diabetes Care.

Recruiting
Registry status
800
Enrollment target
2
Study locations

NCT06668935 is a study of Diabetes Mellitus that is actively recruiting participants, run by Abbott Diabetes Care. The registered enrollment target is 800 participants, below the 1,864-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06668935, a study of Diabetes Mellitus, is actively recruiting participants, sponsored by Abbott Diabetes Care.

RECRUITING
Registry status
800 participants
Enrollment target
2
Study locations

Study Summary

This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.

Conditions Studied

Interventions

  • DEVICE To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists

Study Locations (2)

Florida

  • East Coast Institute for Research, LLC - Jacksonville
  • Excellence Medical and Research - Miami Gardens

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2024-10-24
Est. Completion 2027-01

Sponsor

Abbott Diabetes Care

26 total trials

What the Registry Record Tells You About NCT06668935

The ClinicalTrials.gov registry entry for NCT06668935 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,864-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (57% lower). The listed sponsor is Abbott Diabetes Care, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists is the first listed.

NCT06668935 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06668935 about?

NCT06668935 is a clinical study titled "Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring". This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.

What is the current status of trial NCT06668935?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2024-10-24. Estimated completion is 2027-01.

What conditions does trial NCT06668935 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT06668935?

The interventions under investigation include: To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists (DEVICE).

Who is sponsoring clinical trial NCT06668935?

This trial is sponsored by Abbott Diabetes Care, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06668935 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.